Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EGFR-IN-39, an acrylamide derivative, is a potent inhibitor of EGFR. EGFR-IN-39 is an antitumor agent with low toxicity and side effects. Among them, the overexpression and mutation of epidermal growth factor receptor (EGFR) have been clearly confirmed to cause uncontrollable cell growth, and are related to the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential to study EGFR mutation-related diseases.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | EGFR-IN-39, an acrylamide derivative, is a potent inhibitor of EGFR. EGFR-IN-39 is an antitumor agent with low toxicity and side effects. Among them, the overexpression and mutation of epidermal growth factor receptor (EGFR) have been clearly confirmed to cause uncontrollable cell growth, and are related to the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential to study EGFR mutation-related diseases. |
分子量 | 480.95 |
分子式 | C24H25ClN6O3 |
CAS No. | 2711105-48-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EGFR-IN-39 2711105-48-3 Inhibitor inhibitor inhibit